Motley Fool Podcasts

Mylan launches a generic "at-risk" and Flexion's big drug opportunity becomes clearer.

Editor's note: Mylan's drug was mistakenly referred to in the episode as a biosimilar. Copaxone, however, was approved under an NDA, not a BLA, so Mylan's copycat is a generic, not a biosimilar.